Study | Exclusion reasons | Remarks | Reference(s) | ||
---|---|---|---|---|---|
CheckMate 511, 2019 | randomized controlled trial | phase IIIb/IV | |||
Amaria, 2018 | - | inadequate or absent control group |
Amaria Nat. Med. 2018; 24:1649-1654 10.1038/s41591-018-0197-1 |
||
Hersh, 2011 | - | inadequate or absent control group |
Hersh Invest New Drugs 2011; 29:489-98 10.1007/s10637-009-9376-8 |
||
Wolchok, 2010 | - | inadequate or absent control group |
Wolchok Lancet Oncol. 2010; 11:155-64 10.1016/S1470-2045(09)70334-1 |
||
Blank, 2018 | - | not relevant study design |
Blank Nat. Med. 2018; 24:1655-1661 10.1038/s41591-018-0198-0 |
||
Long, 2018 | - | not relevant study design |
Long Lancet Oncol. 2018; 19:672-681 10.1016/S1470-2045(18)30139-6 |
||
Lebbé, 2019 | - | not relevant outcome | |||
OpACIN-neo, 2019 | - | not relevant outcome |
Rozeman, E.A. The Lancet Oncology 2019; 20:948-. 10.1016/S1470-2045(19)30151-2 |